Open Access

Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation


1Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan

2Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan

3Division of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan

4Division of Respiratory Medicine, Hitachinaka Medical Center, University of Tsukuba, Hitachinaka, Japan

Cancer Diagnosis & Prognosis Mar-Apr; 3(2): 244-250 DOI: 10.21873/cdp.10208
Received 25 November 2022 | Revised 07 December 2023 | Accepted 06 December 2022
Corresponding author
Hiroaki Satoh, MD, Ph.D., Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, 3100015, Mito, Ibaraki, Japan. Tel: +81 292312371, Fax: +81 292215137, email:


Background/Aim: Immune checkpoint inhibitors (ICIs) have revolutionized advanced non-small cell lung cancer (NSCLC) treatment. Even patients with epidermal growth factor receptor (EGFR)-mutated NSCLC may choose an ICI after failure of EGFR-tyrosine kinase inhibitor treatment. ICI-mediated immune-related adverse events (irAEs) may prompt NSCLC patients to discontinue their treatment. This study evaluated the effect of ICI treatment discontinuation on the prognosis of patients with EGFR-mutated NSCLC. Patients and Methods: We performed a retrospective study that reviewed the clinical courses of patients with EGFR-mutated NSCLC treated with ICI therapy from February 2016 to February 2022. ‘Discontinuation’ was defined as failure to receive at least two treatment courses of ICI due to grade 2 irAEs (grade 1 in the lung) or higher in patients responding to ICI. Results: During the study period, 13 of 31 patients discontinued ICI therapy due to irAEs. Survival from the initiation of ICI therapy was significantly longer in patients who discontinued ICI therapy compared with those who did not discontinue. In uni- and multivariate analyses, ‘discontinuation’ was a favourable factor. There was no significant difference in survival from ICI initiation between patients with grade 3 or higher irAEs and those with grade 2 or lower irAEs. Conclusion: In this patient cohort, discontinuation of ICI therapy due to irAEs did not adversely affect prognosis in patients with EGFR-mutant NSCLC. Our results suggest that when treating patients with EGFR-mutant NSCLC with ICIs, chest physicians should consider discontinuing ICI with close monitoring.
Keywords: Immune checkpoint inhibitor, discontinuation, nonsmall cell lung cancer, Epidermal growth factor receptor, EGFR, driver mutation

Immune checkpoint inhibitors (ICIs) have transformed treatment for many advanced carcinomas including non-small cell lung cancer (NSCLC) (1-4). The long-tailed plateau of survival curves in patients receiving ICI therapy is extremely positive, with a considerable cure rate in patients with advanced NSCLC (1-4). With conventional cytotoxic anti-tumour drugs, dosing and treatment intervals are determined by pharmacokinetics and pharmacodynamics, such as drug half-life and blood concentrations (5). The therapeutic effect might be expected to decline if the drug is discontinued for some reasons. However, some previous studies have shown that the prognosis of patients who discontinue ICI therapy due to immune-related adverse events (irAEs) does not necessarily worsen (6-19). To our knowledge however, there have been no prospective studies that clearly show discontinuation of ICIs due to irAEs does not impair prognosis.

ICI therapy for NSCLC patients has been primarily performed in those negative for driver mutations. In NSCLC patients with driver mutations, specific tyrosine kinase inhibitors (TKIs) are usually selected as first-line therapy, but these patients are commonly difficult to cure. ICI therapy is an attractive treatment due to its long-tailed survival curve plateau. As such, ICIs are likely to be the therapy of choice for the second and subsequent treatment lines in patients with driver gene-positive NSCLC. The impact of discontinuation of ICI therapy has not been established in patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC, where previous studies were only in small numbers of patients (15,16). As such, we conducted this study with the aim of clarifying the clinical significance of ICI discontinuation in patients with EGFR mutation-positive NSCLC.

Patients and Methods

Patients. The medical records of all consecutive patients diagnosed with NSCLC in our three tertiary hospitals between February 2016 and February 2022 were examined. All patients with NSCLC who received ICI therapy, whether as monotherapy or in combination with chemotherapy, were included in the study. NSCLC was diagnosed using the classification of the World Health Organization. The clinical stage was assessed according to the TNM classification (8th Edition) (20) using computed tomography scans or magnetic resonance imaging of the head, bone scans, and ultrasonography and/or computed tomography of the abdomen in all patients prior to ICI therapy initiation. In all the NSCLC patients, EGFR mutation was evaluated by cobas® EGFR Mutation Test v2 (Roche Diagnostics, Tokyo, Japan) or Oncomine Dx Target Test Multi-CDx system (Life Technologies, Tokyo, Japan) using bronchoscopic or surgically resected tissue specimens prior to initiation of systemic therapy including TKIs.

Background patient data, such as age, sex, Eastern Cooperative Oncology Group score for performance status, histopathology, disease stage and programmed death ligand 1 (PD-L1) expression were obtained from the patients’ medical records. Objective tumour response was evaluated according to Response Evaluation Criteria in Solid Tumours guidelines (version 1.1) (21). All irAEs were evaluated according to the Common Terminology Criteria for Adverse Events (version 5.0) (22).

Discontinuation of ICI. The reason for ICI discontinuation was extracted from the patients’ medical records. ‘Discontinuation’ was defined as failure to receive at least two treatment courses of ICI due to grade 2 irAEs (grade 1 in the lung) or higher in patients who had ‘partial response’ or ‘complete response’ status ICI. In other words, patients that requested to discontinue ICI therapy while in a ‘progressive disease’ state of lung cancer were not included in the ‘discontinuation’ group.

Statistical analysis. For comparing nominal variables, we used the χ2 test. To compare values with unknown variance, we used the nonparametric Mann-Whitney test. We used progression free survival (PFS) and overall survival (OS) to assess the duration of therapy. In addition, we evaluated survival from the initiation of the first ICI therapy until the last follow-up. Survival time was estimated by the Kaplan-Meier method and compared using the log rank test. We used the Cox proportional hazards model and the forward-backward stepwise method to determine the independent variables used in the final model. All statistical analyses were conducted using SPSS, version 23 (IBM Corporation, Armonk, NY, USA). A p-value of less than 0.05 was considered significant.

Ethics. This study conformed to the Ethical Guidelines for Clinical Studies issued by the Ministry of Health, Labour, and Welfare of Japan. Written informed consent for a non-interventional retrospective study was obtained from each patient. Analysis of patient medical records was approved by the ethics committee of the Mito Medical Centre, University of Tsukuba (NO 20-57).


Clinicopathological features of patients treated with ICI. During the study period, 31 EGFR-positive patients received ICIs as second or later-line therapy after EGFR-TKIs. Thirteen of the 31 patients (41.9%) discontinued ICI treatment due to irAEs (10 after ICI monotherapy, 3 after chemotherapy plus ICI). The median (range) length of discontinuation was 3.0 (2.0-27.0) months. The remaining 18 patients did not discontinue ICI treatment. No patient continued ICI treatment despite the appearance of a grade 2 or higher irAE (respiratory grade 1 or higher irAE). Table I compares patient backgrounds. There were no significant differences in patient characteristics between the groups with and without discontinuation of ICI therapy. At the end of the study period, 25 of the 31 patients had died, four were undergoing anti-cancer treatment, and two were transferred to a palliative care facility.

Comparison of patients with or without discontinuation of ICI. Figure 1 shows OS, treatment details and clinical course from the initiation of first-line therapy of the 31 patients who did or did not have ICI discontinuation. The median (range) OS from the initiation of EGFR-TKI until the last follow-up in patients with or without ICI discontinuation was 44.0 (11.0-79.0) and 27.0 (12.0-132.0) months, respectively. These values were not significantly different (p=0.459).

Details of treatment and survival from initiation of ICI therapy until last follow-up in the two groups of patients are shown in Figure 2. The median (range) length of survival from initiation of ICI until the last follow-up in patients with and without ICI discontinuation was 13.0 (2.0-56.0) and 8.0 (2.0-39.0) months, respectively; which were significantly different (p=0.040).

Contribution of ICI discontinuation to survival. Since there was no difference in background characteristics between patients with or without ICI discontinuation, factor analysis for survival from ICI initiation until the last follow-up was performed. As shown in Table II, univariate analysis revealed that ‘presence of PD-L1 expression’ and ‘discontinuation of ICI therapy’ contributed to survival. Multivariate analysis confirmed discontinuation of ICI due to irAEs as a favourable factor that contributed to patient survival.

Patients with discontinuation of ICI. The clinicopathological features of each of the 13 patients who discontinued ICI therapy are shown in Table III. Eight patients had irAEs of grade 2 or less and five had irAEs of grade 3-4. For survival from the initiation of ICI treatment to final follow-up, we examined age (70 years and older, under 70 years), sex, EGFR gene mutation type (Exon 19 deletion, others), PD-L1 expression (none, 1% or more), ICI (PD-L1 antibody, PD-1 antibody), ICI administration method (single agent, chemotherapy combination), and irAE (up to grade 2, grade 3 and higher). There were no significant differences between groups (p-values: 0.181, 0.772, 0.564, 0.107, 0.734, 0.962 and 0.271, respectively).

Treatment after ICI discontinuation was performed in nine patients (chemotherapy in 5, TKIs in 3, and ICI in 1 patient). No irAEs occurred in the patient re-challenged with ICI.


In the present study, treatment courses for 31 patients who had ICI therapy at any stage were investigated in detail. Thirteen patients had discontinuation of ICI-containing therapy due to grade 2 or higher irAEs (or grade 1 or higher pulmonary irAEs). The median (range) length of discontinuation was 3.0 (2.0-27.0) months. There was no difference in the clinicopathological backgrounds of the 13 patients who discontinued ICI therapy and the 18 patients who did not, and there was no difference in OS between the two groups. However, survival from the initiation of ICI therapy was significantly longer in the 13 patients who discontinued ICI therapy compared with the 18 patients who did not. In uni- and multivariate analyses, “discontinuation of ICI therapy due to irAEs” was a favourable factor. There was no significant difference in survival from initiation of ICI to final follow-up between patients with irAEs grade 3 or higher, and those with grade 2 or lower irAEs. These data indicate discontinuation of ICI due to irAEs occurring during treatment response period could be an acceptable treatment option. Of course, in such cases, continuous image evaluation for the presence or absence of recurrence would be essential.

In driver gene-negative NSCLC patients treated with ICIs, it is common to encounter patients who have had to discontinue treatment due to, for example, the occurrence of irAEs. In such cases, these patients may change to a treatment other than ICI or discontinue ICI therapy (23). Several studies have been conducted on ICI discontinuation in driver mutation-negative NSCLC (6-16). Many of these studies found discontinuation did not adversely affect prognosis, indicating discontinuation could be chosen without hesitation in situations where discontinuation is necessary (6-16). However, there are no universal guidelines regarding the rationale and conditions for discontinuation, meaning decisions would need to be made on a case-by-case basis. However, in patients with EGFR gene mutation NSCLC, treatment with EGFR-TKI has been established as the standard therapy (24) and usually selected as first-line treatment. However, cure with EGFR-TKIs is considered impossible. Therefore, incorporation of other treatments into the TKI treatment regimen needs further exploration. Some years ago, osimertinib after nivolumab treatment was associated with a high risk of developing drug-induced lung injury (25,26). However, there have been no further reports of this association, perhaps due to an avoidance of these treatments in this order. Despite these circumstances, there is increasing evidence that ICI is a useful option for patients with EGFR-mutated NSCLC. While there have been some reports on ICI discontinuation in patients that included those with EGFR-mutated NSCLC (15,16), these studies did not perform any specific prognostic sub-analysis in these patients. Therefore, our current study is the first to focus on ICI discontinuation in NSCLC patients with an EGFR driver mutation.

This study presented some interesting findings, but also had some limitations. First, this study was retrospective in nature with a small number of patients. As such the analysis grouped several different ICIs together. Using data from a larger number of patients would allow analysis of ICI discontinuation across discrete ICIs. Similarly, patients treated with ICI monotherapy and those treated with chemotherapy and ICI should ideally have been analysed separately. Second, in this study, discontinuation was defined as failure to receive at least two treatment courses due to irAEs of grade 2 (grade 1 in the lung) or higher but it was unclear whether the period of discontinuation was appropriate. Therefore, a clear and universally acceptable definition of ‘discontinuation of ICI therapy’ is required. Third, there is the possibility that the evaluation of ICI discontinuation was simply that of irAEs. In other words, the patients who underwent ICI discontinuation were exactly the same patients who developed irAEs, thus the results obtained could be interpreted as the result of irAEs development. Continuing ICI in patients with severe irAEs is ethically inappropriate. Therefore, since it is difficult to analyse these two separately, it was a limitation that could not be analysed separately in this study. Despite these limitations, this study, which more reflects actual clinical practice, provided preliminary indications that warrant further study. It might be informative to divide patients into two groups, one with ICI discontinuation and the other without discontinuation at the time of appearance of irAEs and compare the prognosis between these two groups. However, it might be difficult to design an optimal prospective comparative study when it remains debatable what treatment the control group should receive. As such, an alternative could be to collect and analyse the results of as many patients as possible in a retrospective manner.


It would not be appropriate to recommend discontinuation of ICI based on the results of this study alone. However, discontinuation of ICI might be an option if severe irAEs develop that require ICI discontinuation, or the patient choses discontinuation even though responding to ICI treatment. A prospective clinical trial with discontinuation of ICI as a study arm should be considered in the future. In all cases, however, regardless of whether discontinuation of ICI occurs, close attention should be paid to monitoring for recurrence.

Conflicts of Interest

The Authors have no conflicts of interest to declare in relation to this study.

Authors’ Contributions

SO, SH, TS, KM and HS designed the study. SO, SH, TS, KM and HS collected the data. SO, SH and HS analysed the data. SO, SH, HS and NH prepared the manuscript. HY, HS, and NH supervised the study. All Authors approved the final version for submission.


1 Akhbariyoon H Azizpour Y Esfahani MF Firoozabad MSM Rad MR Esfahani KS Khoshavi N Karimi N Shirinisaz A Abedi F Rad MR & Sharifi P Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol. 232 108873 2021. PMID: 34688855. DOI: 10.1016/j.clim.2021.108873
2 Boussageon M Swalduz A Chouaïd C & Bylicki O First-line treatment of advanced non-small-cell lung cancer with immune-checkpoint inhibitors: New combinations and long-term data. BioDrugs. 36(2) 137 - 151 2022. PMID: 35147894. DOI: 10.1007/s40259-022-00515-z
3 Fiala O Sorejs O Sustr J Kucera R Topolcan O & Finek J Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors. Anticancer Res. 40(3) 1219 - 1227 2020. PMID: 32132018. DOI: 10.21873/anticanres.14063
4 Nieder C Aanes SG & Haukland EC Survival and early death within three months from the start of immune checkpoint inhibitors in patients with different types of cancer. Anticancer Res. 42(6) 3061 - 3066 2022. PMID: 35641252.
Pubmed |
5 Kaye SB Workman P Graham MA Cassidy J & Jodrell D Pharmacokinetics and early clinical studies of selected new drugs. Cancer Surv. 17 371 - 396 1993. PMID: 8137348.
Pubmed |
6 Kimura H Araya T Yoneda T Shirasaki H Kurokawa K Sakai T Koba H Tambo Y Nishikawa S Sone T & Kasahara K Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond). 39(1) 78 2019. PMID: 31753015. DOI: 10.1186/s40880-019-0423-3
7 Tachihara M Negoro S Inoue T Tamiya M Akazawa Y Uenami T Urata Y Hattori Y Hata A Katakami N & Yokota S Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer. 18(1) 946 2018. PMID: 30285770. DOI: 10.1186/s12885-018-4819-2
8 Yilmaz M & Guven Mese S Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients. J Oncol Pharm Pract. 26(3) 761 - 767 2020. PMID: 31423946. DOI: 10.1177/1078155219867131
9 Topalian SL Sznol M McDermott DF Kluger HM Carvajal RD Sharfman WH Brahmer JR Lawrence DP Atkins MB Powderly JD Leming PD Lipson EJ Puzanov I Smith DC Taube JM Wigginton JM Kollia GD Gupta A Pardoll DM Sosman JA & Hodi FS Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32(10) 1020 - 1030 2014. PMID: 24590637. DOI: 10.1200/JCO.2013.53.0105
10 Jansen YJL Rozeman EA Mason R Goldinger SM Geukes Foppen MH Hoejberg L Schmidt H van Thienen JV Haanen JBAG Tiainen L Svane IM Mäkelä S Seremet T Arance A Dummer R Bastholt L Nyakas M Straume O Menzies AM Long GV Atkinson V Blank CU & Neyns B Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 30(7) 1154 - 1161 2019. PMID: 30923820. DOI: 10.1093/annonc/mdz110
11 McDermott DF Drake CG Sznol M Choueiri TK Powderly JD Smith DC Brahmer JR Carvajal RD Hammers HJ Puzanov I Hodi FS Kluger HM Topalian SL Pardoll DM Wigginton JM Kollia GD Gupta A McDonald D Sankar V Sosman JA & Atkins MB Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 33(18) 2013 - 2020 2015. PMID: 25800770. DOI: 10.1200/JCO.2014.58.1041
12 Haratani K Hayashi H Chiba Y Kudo K Yonesaka K Kato R Kaneda H Hasegawa Y Tanaka K Takeda M & Nakagawa K Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4(3) 374 - 378 2018. PMID: 28975219. DOI: 10.1001/jamaoncol.2017.2925
13 Reck M Ciuleanu TE Cobo M Schenker M Zurawski B Menezes J Richardet E Bennouna J Felip E Juan-Vidal O Alexandru A Sakai H Lingua A Reyes F Souquet PJ De Marchi P Martin C Pérol M Scherpereel A Lu S Paz-Ares L Carbone DP Memaj A Marimuthu S Zhang X Tran P & John T First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 6(5) 100273 2021. PMID: 34607285. DOI: 10.1016/j.esmoop.2021.100273
14 Iivanainen S & Koivunen JP Early PD-1 therapy discontinuation in responding metastatic cancer patients. Oncology. 96(3) 125 - 131 2019. PMID: 30380551. DOI: 10.1159/000493193
15 Kim H Kim DW Kim M Lee Y Ahn HK Cho JH Kim IH Lee YG Shin SH Park SE Jung J Kang EJ & Ahn MJ Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer. 128(4) 778 - 787 2022. PMID: 34705268. DOI: 10.1002/cncr.33984
16 Bilger G Girard N Doubre H Levra MG Giroux-Leprieur E Giraud F Decroisette C Carton M & Massiani MA Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother. 71(7) 1719 - 1731 2022. PMID: 34821950. DOI: 10.1007/s00262-021-03114-z
17 Shao J Wang C Ren P Jiang Y Tian P & Li W Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 40(5) BSR20192347 2020. PMID: 32315071. DOI: 10.1042/BSR20192347
18 Hsiehchen D Naqash AR Espinoza M Von Itzstein MS Cortellini A Ricciuti B Owen DH Laharwal M Toi Y Burke M Xie Y & Gerber DE Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology. 11(1) 2017162 2022. PMID: 35003896. DOI: 10.1080/2162402X.2021.2017162
19 Osawa H Shiozawa T Okauchi S Miyazaki K Kodama T Kagohashi K Nakamura R Satoh H & Hizawa N Association between time to treatment failure and peripheral eosinophils in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Pol Arch Intern Med. 131(10) 16049 2021. PMID: 34180611. DOI: 10.20452/pamw.16049
20 Goldstraw P Chansky K Crowley J Rami-Porta R Asamura H Eberhardt WE Nicholson AG Groome P Mitchell A Bolejack V International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions & International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11(1) 39 - 51 2016. PMID: 26762738. DOI: 10.1016/j.jtho.2015.09.009
21 Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R Dancey J Arbuck S Gwyther S Mooney M Rubinstein L Shankar L Dodd L Kaplan R Lacombe D & Verweij J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2) 228 - 247 2009. PMID: 19097774. DOI: 10.1016/j.ejca.2008.10.026
22 Common Terminology Criteria for Adverse Events (CTCAE) Version 5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.. Available at:
23 Hattori S Okauchi S Sasatani Y Ohara G Miyazaki K Sato S Kodama T Shiozawa T Satoh H & Hizawa N Discontinuation of immune checkpoint inhibitor and survival in patients with non-small-cell lung cancer without a driver gene mutation. Anticancer Res. 42(9) 4589 - 4595 2022. PMID: 36039463. DOI: 10.21873/anticanres.15962
24 Passiglia F Bironzo P Bertaglia V Listì A Garbo E & Scagliotti GV Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 11(5) 935 - 949 2022. PMID: 35693274. DOI: 10.21037/tlcr-22-1
25 Schoenfeld AJ Arbour KC Rizvi H Iqbal AN Gadgeel SM Girshman J Kris MG Riely GJ Yu HA & Hellmann MD Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 30(5) 839 - 844 2019. PMID: 30847464. DOI: 10.1093/annonc/mdz077
26 Uchida T Kaira K Yamaguchi O Mouri A Shiono A Miura Y Hashimoto K Nishihara F Murayama Y Kobayashi K & Kagamu H Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer. 10(4) 975 - 979 2019. PMID: 30864291. DOI: 10.1111/1759-7714.13039